8.85  0.04 (0.45%)		02-13 16:00
Open: 8.91 High: 9.18 Volume: 2,090,474		Pre. Close: 8.81 Low: 8.61 Market Cap: 875(M)

Short term
Mid term
Targets	6-month :	13.33	1-year :	15.35
Resists	First :	11.41	Second :	13.14
Pivot price	9.89
Supports	First :	8.6	Second :	7.16
MAs	MA(5) :	9.37	MA(20) :	10.03
	MA(100) :	9.96	MA(250) :	12.39
MACD	MACD :	-0.5	Signal :	-0.3
%K %D	K(14,3) :	11.3	D(3) :	15.9
RSI	RSI(14): 35.1
52-week	High :	18.89	Low :	6.65

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ SPRY ] has closed below the lower bollinger band by 2.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 15.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	9.19 - 9.24	9.24 - 9.29
Low:	8.48 - 8.54	8.54 - 8.6
Close:	8.75 - 8.85	8.85 - 8.94

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Tue, 10 Feb 2026
ARS Pharmaceuticals to Showcase Scientific Innovation and - GlobeNewswire

Mon, 02 Feb 2026
Needle-free allergy rescue for kids wins key EU support - Stock Titan

Sat, 31 Jan 2026
Lisanti Capital Growth LLC Sells 208,886 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat

Sat, 10 Jan 2026
Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump - Yahoo Finance

Fri, 09 Jan 2026
ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating - Yahoo Finance

Mon, 10 Nov 2025
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	99 (M)
Held by Insiders	1.0541e+008 (%)
Held by Institutions	16.8 (%)
Shares Short	21,590 (K)
Shares Short P.Month	0 (K)

EPS	-8.981e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-56.1 %
Operating Margin	-163.7 %
Return on Assets (ttm)	-19.3 %
Return on Equity (ttm)	-46 %
Qtrly Rev. Growth	1 %
Gross Profit (p.s.)	637.29
Sales Per Share	1.92932e+008
EBITDA (p.s.)	1.5523e+008
Qtrly Earnings Growth	-0.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-85 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	4.39

Dividend	0
Forward Dividend	2.022e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.